Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the potential effect of the sale of the Bexsero form of meningococcal group B vaccine to GlaxoSmithKline on (a) his Department's negotiations with Novartis on a price for the vaccine and (b) the roll out of that vaccine.

As the commercial negotiations with Novartis are confidential and this includes any assessments made to inform the negotiations, it is not possible to provide the information requested.